glp 1 covered by medicare Recent Trends in GLP-1 Use and Spending in New Medicare GLP-1 Bridge Program

Avoid smoking : Smoking is also linked to a higher risk of pancreatitis

Archived from the original (PDF) on 14 January 2024

Research has identified these alarming vision-related risks associated with GLP-1 medications: Sudden irreversible vision loss: NAION strikes without warning, often discovered upon waking, causing blurry or dim vision that progresses to immediate and permanent partial or complete blindness in the affected eye with no possibility of restoration Elevated risk across multiple studies: Beyond the Harvard findings showing 4-7 fold increased risk, a University of Southern Denmark study examining over 424,000 patients found weekly semaglutide users faced 2.19 times higher NAION risk European regulatory recognition: In June 2025, the European Medicines Agency officially recognized NAION as a possible side effect of semaglutide medications, marking formal acknowledgment by international regulators Complete absence of treatment options: Medical science currently offers no cure, no effective treatment, and no way to reverse NAION-related vision damage, leaving patients with permanent disability The permanent and irreversible nature of NAION-related optic nerve damage distinguishes these injuries from other complications that may resolve after discontinuing medication

Superguts GLP-1 Booster is a prebiotic fiber mix containing resistant starch from green banana powder, beta-glucan from oats, and soluble vegetable fiber

The central question is no longer just whether a clear statistical link exists, but whether manufacturers and regulators exercised appropriate caution while long-term, real-world data is still developing

The data was collected in May 2025